Sign In
Buy CARA
$5.32
+0 (+0%)
At Close: Jul 14, 2025
Cara Therapeutics to Announce First Quarter 2020 Financial Results on May 11, 2020
08:01pm, Monday, 04'th May 2020
STAMFORD, Conn., May 04, 2020 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to.
Cannabis Central: Pot Stock Sector Up 1.7% On Monday; NPSI Up 3.0%
12:00am, Monday, 04'th May 2020Cannabis Central: All But Two NPSI Constituents Declined On Friday
10:26pm, Saturday, 02'nd May 2020
The index tracking the 35 cannabis stocks that trade for US$1/share or more (i.e. 12% of the universe of 298 companies) was down 3.9% on Friday.
We Think Cara Therapeutics (NASDAQ:CARA) Needs To Drive Business Growth Carefully
12:35pm, Saturday, 02'nd May 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Cara Therapeutics Inc (NASDAQ:CARA) Expected to Announce Quarterly Sales of $4.83 Million
09:46am, Friday, 01'st May 2020
Brokerages expect Cara Therapeutics Inc (NASDAQ:CARA) to report sales of $4.83 million for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Cara Therapeutics’ earning
Better Buy: Cara Therapeutics vs. Sangamo Therapeutics
11:14am, Wednesday, 29'th Apr 2020
Take Cara Therapeutics (NASDAQ: CARA) and Sangamo Therapeutics (NASDAQ: SGMO), for example. One thing that both Cara and Sangamo have in common, though, are promising pipeline candidates. Investor
Will Cara Therapeutics (NASDAQ:CARA) Spend Its Cash Wisely?
11:03am, Wednesday, 29'th Apr 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Cara Therapeutics (NASDAQ:CARA) Rating Lowered to Hold at Zacks Investment Research
10:10am, Wednesday, 29'th Apr 2020
Cara Therapeutics (NASDAQ:CARA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks.com rep
Zacks: Analysts Anticipate Cara Therapeutics Inc (NASDAQ:CARA) Will Announce Earnings of -$0.63 Per Share
08:00am, Wednesday, 29'th Apr 2020
Equities analysts expect Cara Therapeutics Inc (NASDAQ:CARA) to report earnings per share (EPS) of ($0.63) for the current quarter, Zacks reports. Five analysts have made estimates for Cara Therapeuti
Earnings Preview: Cara Therapeutics (CARA) Q1 Earnings Expected to Decline
04:34pm, Tuesday, 28'th Apr 2020
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Cara Therapeutics (CARA) Q1 Earnings Expected to Decline
04:34pm, Tuesday, 28'th Apr 2020
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cara Therapeutics Inc (NASDAQ:CARA) Shares Sold by Nuveen Asset Management LLC
10:54am, Monday, 27'th Apr 2020
Nuveen Asset Management LLC trimmed its stake in shares of Cara Therapeutics Inc (NASDAQ:CARA) by 22.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Com
FY2020 EPS Estimates for Cara Therapeutics Inc (NASDAQ:CARA) Lifted by Analyst
08:56am, Saturday, 25'th Apr 2020
Cara Therapeutics Inc (NASDAQ:CARA) – Cantor Fitzgerald raised their FY2020 earnings per share (EPS) estimates for Cara Therapeutics in a research note issued to investors on Wednesday, April 22nd.
Cara Therapeutics (NASDAQ:CARA) Upgraded to Buy at Zacks Investment Research
07:48am, Saturday, 25'th Apr 2020
Zacks Investment Research upgraded shares of Cara Therapeutics (NASDAQ:CARA) from a hold rating to a buy rating in a research report released on Tuesday morning, Zacks.com reports. The firm currently
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC's IPO & More
02:20pm, Friday, 24'th Apr 2020
COVID-19’s spread has clamped down on a lot of economic activity, including the work of developing and testing new medicines. But the FDA isn’t showing
